News | November 07, 2022
Balaxi Pharmaceuticals delivers strong growth in Q2 FY23
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Revenue is up 23% whereas Profit After Tax expands 29% for the company
API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories
The company has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Results reinforce commitment to next-generation oral SERD development programme
CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus
Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone
Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
Subscribe To Our Newsletter & Stay Updated
